Response to specific anti-oestrogen (ICI182780) in tamoxifen-resistant breast cancer

The Lancet

Volumn 345, Issue 8948, 1995, Pages 525-

  Dowsett, M ^a   Johnston, S R D ^a   Iveson, T J ^a   Smith, I E ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR; FULVESTRANT; IDOXIFENE; LETROZOLE; TAMOXIFEN; TOREMIFENE; VOROZOLE;

BREAST CANCER; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESISTANCE; FEMALE; HUMAN; LETTER; META ANALYSIS; METHODOLOGY; PATIENT SELECTION; PRIORITY JOURNAL;

EID: 0028926203     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(95)90624-X     Document Type: Letter

References (3)

1. Phase I study of oral aromatase inhibitor CGS20267 in postmenopausal patients with breast cancer
2. The clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer
3. Pyrrolodine-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antioestrogen tamoxifen for the treatment of breast cancer